ClinicalTrials.gg
Status unknownNCT01613729Cor16Updated Sep 25, 2012

Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin

A Phase 4 interventional study of Rosuvastatin 5 mg and Rosuvastatin 10 mg in Dyslipidemia, sponsored by D16 Pharma & Biotec Ltd.. Status unknown at 1 site in Bangladesh. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-09-25.

Sponsored by D16 Pharma & Biotec Ltd. · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2012), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing rosuvastatin in Dyslipidemias — 2 open to participants now, 2 under way, none of them phase 3. rosuvastatin · Dyslipidemias.

Planned enrollment
5th of 42
2,000 · median 128
Started
2012
with 1 other
Phase 4
13 of 42
1 open now
Registered
14th of 42
by date
Lead sponsor
1 of 42
D16 Pharma & Biotec Ltd.

Among the 42 studies testing rosuvastatin in Dyslipidemias, this one is the 5th largest by planned enrollment, is one of 2 that started in 2012, is one of 13 in phase 4, and was the 14th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

2 of the 42 studies testing rosuvastatin in Dyslipidemias are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing rosuvastatin in Dyslipidemias, or all of them as a file.
02

Study summary

The primary objective of the study is to compare the efficacy of Rosuvastatin 5 mg once daily with Rosuvastatin 10 mg once daily by assessment of the number of patients with hypercholesterolemia reaching the LDL-C target goal of \<100 mg/dL after 12 weeks of therapy.

Read the detailed description

This study will observe the followings:

  1. To compare the effect of 5 mg/10 mg Rosuvastatin by assessment of the number of patients reaching LDL-C target goal after 24 weeks of therapy.
  2. To compare the effect of 12 weeks therapy with 5 mg/10 mg Rosuvastatin on change in LDL-C (compare change from baseline).
  3. To investigate the effect of 12 weeks therapy with 10 mg Rosuvastatin on change in LDL-C (compare values week 0 vs. week 12).
  4. To investigate the safety of Rosuvastatin in regards to liver enzyme change, kidney function and muscle toxicity.
  5. To compare the effect of 12 weeks therapy with 5 mg/10 mg Rosuvastatin on change in TC, HDL-C, TG, LDL-C density and HbA1c (compare change from baseline).
  6. To investigate the effect of 12 weeks therapy with 10 mg Rosuvastatin on change in TC, HDL-C, TG, LDL-C density and HbA1c (compare values week 0 vs. week 12).
  7. To investigate the effect of 12 weeks therapy on change in microalbuminuria in each treatment group (compare change from baseline).
  8. To investigate the effect of 12 weeks therapy on change in BMI (compare change from baseline).

    The effects of the dose increase and the dose decrease from weeks 12 to 24 will be evaluated as follows:

  9. To investigate the change in LDL-C by increasing the dose from 5 mg to 10 mg (compare values week 12 vs. 24).
  10. To investigate the change in LDL-C by decreasing the dose from 10 mg to 5 mg (compare values week 12 vs. 24).
  11. To investigate the change in TC, HDL-C, TG, LDL-C density and HbA1c by increasing the dose from 5 mg to 10 mg (compare values week 12 vs. 24).
  12. To investigate the change in TC, HDL-C, TG, LDL-C density and HbA1c by decreasing the dose from 10 mg to 5 mg (compare values week 12 vs. 24).
03

Conditions studied

  • Dyslipidemia

Browse trials for

Keywords

  • Dyslipidemia
  • Rosuvastatin
  • Efficacy
  • Safety
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 45 - 75 years
  • LDL - C between 130 mg/dL and 250 mg/dL
  • TG \< 400 mg/dL
  • \< 7%
  • Written to participate in the trial

Exclusion criteria

Exclusion Criteria:

  • Known or history of SAE with another HMG-CoA reductase inhibitor, in particular any history of myopathy
  • Active liver disease/severe hepatic impairment
  • Treatment with cyclosporin or any disallowed drug
  • Patients with unstable angina pectoris
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Active comparator
    Rosuvastation 5 Initiator Arm

    These patients will start the study with Rosuvastatin 5 mg and then after 12 weks they will be switched to Rosuvastatin 10 mg.

    Drug: Rosuvastatin 5 mg

  • Active comparator
    Rosuvastatin 10 initiator arm

    These patients will continue with Rosuvastatin 10 mg and after 12 weeks they will be switched to Rosuvastatin 5 mg

    Drug: Rosuvastatin 10 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy of Rosuvastatin 5 mg once daily with Rosuvastatin 10 mg once daily by assessment of the number of patients with hypercholesterolemia reaching the LDL-C target goal of <100 mg/dL after 12 weeks of therapy.

    Time frame: 24 weeks

Secondary outcomes

  1. To compare the safety

    To investigate the effect of 12 weeks therapy on change in microalbuminuria in each treatment group (compare change from baseline). To investigate the effect of 12 weeks therapy on change in BMI (compare change from baseline). The effects of the dose increase and the dose decrease from weeks 12 to 24 will be evaluated to investigate the safety of Rosuvastatin in regards to Liver enzyme change, kidney function and muscle toxicity.

    Time frame: 24 weeks

07

Study locations

1 site
  • BSMMU
    Dhaka, 1000, Bangladesh
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jul 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2012
First posted
Jun 7, 2012
Start
Jul 2012
Primary completionEst.
Jul 2013
CompletionEst.
Dec 2013
Last update
Sep 25, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01613729
Lead sponsor
D16 Pharma & Biotec Ltd.
Collaborators
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, Dhaka Medical College, National Institute of Cardiovascular Diseases
Responsible party
Sponsor
First posted
Jun 7, 2012
Start date
Jul 2012
Primary completion
Jul 2013 (estimated)
Completion
Dec 2013 (estimated)
Last update
Sep 25, 2012

Study contacts

Nazrul Islam, FCPS
principal investigator · Professor of Cardiology
Pinaki Bhattacharya, MBBS
study director · D16 Pharma & Biotec

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion